Tagrisso – Genprex

Genprex Announces Safety Review Committee Approves Dose Escalation in Acclaim-1 Phase 1/2 Trial of REQORSA™ in Combination with Tagrisso® in Non-Small Cell Lung Cancer

August 15, 2022Kalyn Dabbs Acclaim 2 Press Releases

Genprex Announces Safety Review Committee Approves Dose Escalation in Acclaim-1 Phase 1/2 Trial of REQORSA™ in Combination with Tagrisso® in Non-Small Cell Lung Cancer

Recommends Advancing Acclaim-1 to Increased Dose in Second Cohort of Phase 1 Portion of Trial

Genprex Announces Centralized Institutional Review Board Approval for Acclaim-1 Clinical Trial in Non-Small Cell Lung Cancer

May 5, 2021Kalyn Dabbs Acclaim 2 Press Releases

Genprex Announces Centralized Institutional Review Board Approval for Acclaim-1 Clinical Trial in Non-Small Cell Lung Cancer

Company achieves another milestone relating to its clinical trial strategy

Designed and Secured by Barsec

Copyright ©2024 all rights reserved.
Home - Privacy Policy - Terms of Use